Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.68% 0.21% 236.95M 27223.57
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 28.00% 178.34M Upgrade

Basic Info

Investment Strategy
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Healthcare Technology and Innovation Index. The fund will normally invest at least 80% of its total assets in securities of the index or in depositary receipts representing securities of the index. The index is designed to measure the performance of companies that have a portion of their business and revenue derived from the field of healthcare technology, and the potential to grow within this space through innovation and market adoption of such companies’ products and services. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Robo Global
Prospectus Benchmark Index
ROBO Gbl Healthcare Tech & Innov PR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Andrew Serowik 2.02 yrs
Travis Trampe 2.02 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 12
178.34M
-4.645B Category Low
7.623B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of June 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of July 30, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
--
--
--
65.01%
8.62%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
15.07%
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
7.51%
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
-0.03%
14.75%
1.51%
-12.90%
50.15%
-1.23%
34.45%
67.26%
3.43%
--
--
-25.62%
13.57%
-20.62%
24.19%
36.52%
-6.51%
As of July 30, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-30-21) 0.00%
30-Day SEC Yield (7-20-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.77
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of July 28, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of July 28, 2021

Asset Allocation

As of July 28, 2021.
Type % Net % Long % Short
Cash 0.20% Upgrade Upgrade
Stock 99.80% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Editas Medicine Inc 1.74% 41.86 -0.10%
DexCom Inc 1.68% 515.51 13.04%
Veracyte Inc 1.68% 44.56 13.59%
Fulgent Genetics Inc 1.66% 92.25 0.36%
Charles River Laboratories International Inc 1.66% 406.92 0.35%
Vocera Communications Inc 1.66% 41.96 0.02%
Danaher Corp 1.65% 297.49 -0.05%
Illumina Inc 1.65% 495.75 0.84%
Thermo Fisher Scientific Inc 1.65% 540.01 1.17%
Intuitive Surgical Inc 1.64% 991.46 1.02%

News

Headline
Wire
Time (ET)

Basic Info

Investment Strategy
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Healthcare Technology and Innovation Index. The fund will normally invest at least 80% of its total assets in securities of the index or in depositary receipts representing securities of the index. The index is designed to measure the performance of companies that have a portion of their business and revenue derived from the field of healthcare technology, and the potential to grow within this space through innovation and market adoption of such companies’ products and services. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Robo Global
Prospectus Benchmark Index
ROBO Gbl Healthcare Tech & Innov PR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Andrew Serowik 2.02 yrs
Travis Trampe 2.02 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-30-21) 0.00%
30-Day SEC Yield (7-20-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.77
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of July 28, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of July 28, 2021

Fund Details

Key Dates
Inception Date 6/24/2019
Last Annual Report Date 4/30/2021
Last Prospectus Date 9/1/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Headline
Wire
Time (ET)